Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Assets (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Non-Current Assets for 16 consecutive years, with $429.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 3.02% year-over-year to $429.8 million, compared with a TTM value of $1.7 billion through Dec 2025, changed 0.1%, and an annual FY2025 reading of $434.7 million, down 2.18% over the prior year.
  • Non-Current Assets was $429.8 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $434.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $444.3 million in Q3 2024 and bottomed at $170.0 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $353.2 million, with a median of $337.4 million recorded in 2023.
  • Peak annual rise in Non-Current Assets hit 71.05% in 2021, while the deepest fall reached 31.05% in 2021.
  • Year by year, Non-Current Assets stood at $300.3 million in 2021, then increased by 5.4% to $316.5 million in 2022, then rose by 22.72% to $388.4 million in 2023, then increased by 14.1% to $443.2 million in 2024, then fell by 3.02% to $429.8 million in 2025.
  • Business Quant data shows Non-Current Assets for ARWR at $429.8 million in Q4 2025, $434.7 million in Q3 2025, and $433.7 million in Q2 2025.